Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database.

Area of Science:

• Pharmacovigilance and Drug Safety
• Ophthalmology
• Data Mining and Biostatistics

Background:

• Ophthalmic prostaglandin analogues are widely used for glaucoma treatment.
• Identifying potential safety signals is crucial for patient well-being.
• The Food and Drug Administration Adverse Event Reporting System (FAERS) is a key resource for pharmacovigilance.

Purpose of the Study:

• To detect potential safety signals associated with ophthalmic prostaglandin analogues.
• To analyze adverse event data from the FAERS database for specific prostaglandin medications.

Main Methods:

• Data mining of the FAERS database was performed.
• Statistical methods including proportional reporting ratio, reporting OR, Bayesian confidence propagation neural network, information component 0.25, and chi-squared were employed.
• Analysis focused on latanoprost, travoprost, tafluprost, and bimatoprost.

Main Results:

• Twelve preferred terms were statistically associated with ophthalmic prostaglandin analogues.
• Notable associations included diabetes mellitus, hypoacusis, malignant mediastinal neoplasm, elevated immunoglobulin E, cataracts, blepharospasm, abnormal blood counts, skin exfoliation, chest discomfort, and dry mouth.
• Specific event counts ranged from one to two.

Conclusions:

• A potential relationship exists between ophthalmic prostaglandin analogues and several adverse events, supported by biological plausibility.
• Events of concern include malignant mediastinal neoplasm, abnormal blood count, elevated immunoglobulin E, diabetes mellitus, blepharospasm, cataracts, chest discomfort, and dry mouth.
• Further research is warranted to confirm or refute these safety signals and identify potential drug-event associations.